Eli Lilly (NYSE:LLY) announced it would appeal a decision by the U.K. health authorities not to recommend the company’s new ...

And other biotech news brought to you by The Readout.

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has announced that Japanese ...

A newly approved Alzheimer’s drug is set to be administered for the first time in Taiwan on Monday, Far Eastern Memorial Hospital in New Taipei City announced yesterday. Kisunla, the brand name of the ...

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...

TAIPEI (Taiwan News) — Far Eastern Memorial Hospital is set to become the first medical institution in Taiwan to administer ...

The UK's state-run health service said Thursday it will not offer two new treatments for Alzheimer's disease, citing high ...

Jim Herlihy, a regional spokesman for the Alzheimer’s Association, will tell you that Kocherhans finds himself in good, if ...

See here for Eisai (ESALF) stock analysis including Leqembi's EU approval, growth potential, and industry valuation amid ...

A U.K. health agency said the Alzheimer's drugs Kisunla and Leqembi are not cost-effective, meaning they won't be offered through the NHS.

Leqembi (lecanemab-irmb) is a prescription drug that’s used to treat Alzheimer’s disease. It comes as a liquid solution that healthcare professionals administer as an intravenous (IV ...